Table 5 Adverse events in patients
Adverse events | patients (n = 200) | |||
|---|---|---|---|---|
grade1(n%) | Grade2(n%) | Grade3(n%) | grade4(n%) | |
Hand and foot syndrome | 45(22.50%) | 38(19.00%) | 32 (16.00%) | 8(4.00%) |
Hypertension | 25(12.50%) | 20(10.00%) | 18 (9.00%) | 7(3.50%) |
Proteinuria | 17(8.50%) | 15(7.50%) | 14 (7.00%) | 3(1.50%) |
Alopecia | 5(2.50%) | 4(2.00%) | 1 (0.50%) | 0 |
Fatigue | 27(13.50%) | 13(6.50%) | 8 (4.00%) | 1(0.50%) |
Decreased appetite | 23(11.50%) | 11(5.50%) | 14 (7.00%) | 2(1.00%) |
Diarrhea | 15(7.50%) | 11(5.50%) | 3 (1.50%) | 0 |
Oral mucositis | 34(17.00%) | 21(10.50%) | 6 (3.00%) | 1(0.50%) |
hoarseness | 6(3.00%) | 4(2.00%) | 7 (3.50%) | 0 |
Abdominal pain | 31(15.50%) | 17(8.50%) | 7 (3.50%) | 1(0.50%) |
Hematotoxicity | 14(7.00%) | 13(6.50%) | 6 (3.00%) | 2(1.00%) |
Rash | 21(10.50%) | 15(7.50%) | 7 (3.50%) | 1(0.50%) |
Vomiting | 11(5.50%) | 9(4.50%) | 5 (2.50%) | 0 |
constipation | 1(0.50%) | 2 (1.00%) | 2 (1.00%) | 0 |
headache | 11(5.50%) | 10(5.00%) | 4 (2.00%) | 1(0.50%) |
Liver dysfunction | 3(1.50%) | 4(2.00%) | 3 (1.50%) | 0 |
Gastrointestinal hemorrhage | 1(0.50%) | 2(1.00%) | 1 (0.50%) | 0 |